Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 5/20 | 0.38 |
| ▸ | PKM | P14618 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | ADAM17 | P78536 | 3/20 | 0.38 |
| ▸ | MMP1 | P03956 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | CCR6 | P51684 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4380777 | 0.90 | ADAM17 (0.40) | LMNAPKMALDH1A1SMN1; SMN2ADAM17 | |
| SCHEMBL4382627 | 0.87 | ADAM17 (0.42) | LMNAPKMALDH1A1SMN1; SMN2POLB | |
| SCHEMBL4385264 | 0.86 | ALDH1A1 (0.40) | LMNAPKMALDH1A1SMN1; SMN2POLB | |
| SCHEMBL4392967 | 0.85 | ADAM17 (0.41) | LMNAALDH1A1SMN1; SMN2POLBADAM17 | |
| SCHEMBL13589015 | 0.85 | CYP3A4 (0.43) | LMNAPKMALDH1A1SMN1; SMN2ADAM17 | |
| SCHEMBL4380262 | 0.85 | LMNA (0.48) | LMNAPKMALDH1A1POLBADAM17 | |
| SCHEMBL8225081 | 0.85 | RORC (0.43) | PKMALDH1A1ADAM17MMP1MEN1 | |
| SCHEMBL4384704 | 0.82 | L3MBTL1 (0.45) | ADAM17MMP1GAAMEN1KMT2A | |
| SCHEMBL4386136 | 0.82 | ADAM17 (0.43) | LMNAPKMALDH1A1SMN1; SMN2POLB | |
| SCHEMBL4379092 | 0.82 | MRGPRX4 (0.45) | LMNAALDH1A1SMN1; SMN2CCR6GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090298878-A1 | OXIME COMPOUNDS AND THE USE THEREOF | PURDUE PHARMA L.P. | 2009-12-03 | — | — | US | disclosed |
| US-20090298878-A1 | OXIME COMPOUNDS AND THE USE THEREOF | PURDUE PHARMA L.P. | 2009-12-03 | — | — | US | disclosed |
| US-20090298878-A1 | OXIME COMPOUNDS AND THE USE THEREOF | PURDUE PHARMA L.P. | 2009-12-03 | — | — | US | disclosed |
| WO-2008008398-A2 | OXIME COMPOUNDS AND THE USE THEREOF | SHIONOGI & CO., LTD. (JP) | 2008-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298878-A1 | OXIME COMPOUNDS AND THE USE THEREOF | KCNN4, CACNA1A, KCNN3 | LMNA 3822/4885PKM 2106/4885ALDH1A1 2105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.